Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Parathyroid Hormone Following Myeloablative Sequential Unrelated Cord Blood Transplantation

NCT00393380 is registered in ClinicalTrials.gov with The Emmes Company, LLC as lead sponsor.

NCT NCT00393380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00393380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Parathyroid Hormone Following Myeloablative Sequential Unrelated Cord Blood Transplantation
Lead sponsor
The Emmes Company, LLC
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2006
Completion date
March 31, 2012
Enrollment
13 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, aplastic, hodgkin disease, leukemia, lymphocytic, acute, leukemia, lymphocytic, chronic, leukemia, myelocytic, acute, leukemia, myeloid, chronic, lymphoma, myelofibrosis